Wolfgang Preiser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2516692/publications.pdf

Version: 2024-02-01

186 papers 15,210 citations

43 h-index 25230 113 g-index

205 all docs

205 docs citations

times ranked

205

22237 citing authors

#	Article	IF	CITATIONS
1	Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy, 2022, 77, 483-491.	1.3	8
2	Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet, The, 2022, 399, 625-626.	6.3	289
3	Tracking the circulating SARS-CoV-2 variant of concern in South Africa using wastewater-based epidemiology. Scientific Reports, 2022, 12, 1182.	1.6	27
4	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	13.7	1,210
5	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. Journal of Virological Methods, 2022, 302, 114471.	1.0	8
6	Sisonke: reaching several goals together. Lancet, The, 2022, 399, 1095-1097.	6.3	1
7	Fatal SARSâ€CoVâ€2 Omicron variant in a young infant: Autopsy findings. Pediatric Pulmonology, 2022, 57, 1363-1365.	1.0	11
8	No point in travel bans if countries with poor surveillance are ignored. Lancet, The, 2022, 399, 1224.	6.3	3
9	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nature Communications, 2022, 13, 1976.	5 . 8	27
10	Challenges and complexities in evaluating severe acute respiratory syndrome coronavirus 2 molecular diagnostics during the COVID-19 pandemic. African Journal of Laboratory Medicine, 2022, 11, 1429.	0.2	3
11	Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. International Journal of Infectious Diseases, 2022, 118, 150-154.	1.5	22
12	Outcomes of laboratoryâ€confirmed <scp>SARSâ€CoV</scp> â€2 infection in the Omicronâ€driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Tropical Medicine and International Health, 2022, 27, 564-573.	1.0	94
13	Delays in HIV-1 infant polymerase chain reaction testing may leave children without confirmed diagnoses in the Western Cape province, South Africa. African Journal of Laboratory Medicine, 2022, 11, .	0.2	O
14	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nature Medicine, 2022, 28, 1785-1790.	15.2	456
15	After the COVID-19 state of disaster in South Africa. Nature Human Behaviour, 2022, 6, 901-901.	6.2	5
16	From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africaâ€"Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality. Clinical Infectious Diseases, 2021, 72, 327-331.	2.9	54
17	HIV false positive screening serology due to sample contamination reduced by a dedicated sample and platform in a high prevalence environment. PLoS ONE, 2021, 16, e0245189.	1.1	1
18	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS ONE, 2021, 16, e0247852.	1.1	45

#	Article	IF	Citations
19	Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine, 2021, 27, 440-446.	15.2	326
20	Multiple Early Introductions of SARS-CoV-2 to Cape Town, South Africa. Viruses, 2021, 13, 526.	1.5	20
21	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	13.7	1,381
22	Wastewater treatment works change the intestinal microbiomes of insectivorous bats. PLoS ONE, 2021, 16, e0247475.	1.1	6
23	Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis. Vaccine, 2021, 39, 3141-3151.	1.7	8
24	Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. BMC Cancer, 2021, 21, 715.	1.1	10
25	Molecular characterisation and epidemiology of enterovirus-associated aseptic meningitis in the Western and Eastern Cape Provinces, South Africa 2018–2019. Journal of Clinical Virology, 2021, 139, 104845.	1.6	9
26	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	5.1	73
27	Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 978-984.	0.9	5
28	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
29	Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV. BMC Gastroenterology, 2020, 20, 226.	0.8	15
30	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. Journal of Clinical Virology, 2020, 129, 104548.	1.6	16
31	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. PLoS ONE, 2020, 15, e0238839.	1.1	3
32	Turnaround times – the Achilles' heel of community screening and testing in Cape Town, South Africa: A short report. African Journal of Primary Health Care and Family Medicine, 2020, 12, e1-e3.	0.3	7
33	A genomics network established to respond rapidly to public health threats in South Africa. Lancet Microbe, The, 2020, 1, e229-e230.	3.4	46
34	Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. Journal of Infection, 2020, 81, 121-130.	1.7	16
35	Optimising influenza vaccination during a SARS-CoV-2 epidemic in South Africa could help maintain the integrity of our healthcare system. South African Medical Journal, 2020, 110, 259.	0.2	2
36	Prevalence of chronic HBV infection in pregnant woman attending antenatal care in a tertiary hospital in Mwanza, Tanzania: a cross-sectional study. BMC Infectious Diseases, 2020, 20, 395.	1.3	8

#	Article	IF	CITATIONS
37	Limiting the spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries. The Lancet Global Health, 2020, 8, e881-e883.	2.9	116
38	Prevalence and risks of hepatitis E virus infection in blood donors from the Western Cape, South Africa. Vox Sanguinis, 2020, 115, 695-702.	0.7	11
39	High positive HIV serology results can still be false positive. IDCases, 2020, 21, e00849.	0.4	6
40	COVID-19: Getting ahead of the epidemic curve by early implementation of social distancing. South African Medical Journal, 2020, 110, 258.	0.2	28
41	COVID-19 in Africa. Public Health, 2020, 185, 60.	1.4	5
42	Viral hepatitis B and C in HIV-exposed South African infants. BMC Pediatrics, 2020, 20, 563.	0.7	2
43	Diagnosis of COVID-19: Considerations, Controversies and Challenges in South Africa. Wits Journal of Clinical Medicine, 2020, 2, 3.	0.0	7
44	Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring. African Journal of Laboratory Medicine, 2020, 9, 1035.	0.2	4
45	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. Southern African Journal of HIV Medicine, 2020, 21, 1115.	0.3	29
46	Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of Congo—Priorities for Achieving Control. American Journal of Tropical Medicine and Hygiene, 2020, 103, 597-602.	0.6	39
47	Academic publishing in pandemic times. South African Journal of Science, 2020, 116, .	0.3	0
48	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
49	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
50	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
51	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. , 2020, 15, e0238839.		0
52	SAT-182-Full length deep sequencing of South African hepatitis B virus isolates reveals increased viral diversity and X-gene deletions in hepatocellular carcinoma patients. Journal of Hepatology, 2019, 70, e709-e710.	1.8	0
53	THU-428-Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation. Journal of Hepatology, 2019, 70, e345.	1.8	0
54	Lessons in diagnostic virology: expected and unexpected sources of error. Reviews in Medical Virology, 2019, 29, e2052.	3.9	23

#	Article	IF	CITATIONS
55	Pooled PCR testing of dried blood spots for infant HIV diagnosis is cost efficient and accurate. BMC Infectious Diseases, 2019, 19, 136.	1.3	7
56	The detection of diverse coronaviruses, including MERS-related coronaviruses, in South African bat populations and their associated ecology in Neoromica capensis. International Journal of Infectious Diseases, 2019, 79, 2-3.	1.5	0
57	Congenital Rubella Syndrome Surveillance in South Africa Using a Sentinel Site Approach: A Cross-sectional Study. Clinical Infectious Diseases, 2019, 68, 1658-1664.	2.9	12
58	Attempted molecular detection of the thermally dimorphic human fungal pathogen Emergomyces africanus in terrestrial small mammals in South Africa. Medical Mycology, 2018, 56, 510-513.	0.3	15
59	HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa. BMC Infectious Diseases, 2018, 18, 214.	1.3	22
60	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	1
61	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	0
62	Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype?. Epidemiology and Infection, 2017, 145, 1910-1912.	1.0	12
63	Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. Journal of Clinical Virology, 2017, 95, 86-89.	1.6	6
64	Moderate levels of preantiretroviral therapy drug resistance in a generalized epidemic. Aids, 2017, 31, 2387-2391.	1.0	6
65	Is hepatitis B birth dose vaccine needed in Africa?. Pan African Medical Journal, 2017, 27, 18.	0.3	16
66	Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience. PLoS ONE, 2017, 12, e0181267.	1.1	32
67	Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial. PLoS ONE, 2016, 11, e0146678.	1.1	18
68	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. AIDS Research and Human Retroviruses, 2016, 32, 80-84.	0.5	15
69	Novel Arenavirus Isolates from Namaqua Rock Mice, Namibia, Southern Africa. Emerging Infectious Diseases, 2015, 21, 1213-1216.	2.0	9
70	The HIV/HBV co-infected patient: Time for proactive management. South African Medical Journal, 2015, 105, 281.	0.2	4
71	Hepatitis E virus infection: An underdiagnosed infection in transplant patients in Southern Africa?. Journal of Clinical Virology, 2015, 70, 23-25.	1.6	9
72	Evolutionary origins of hepatitis A virus in small mammals. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15190-15195.	3.3	99

#	Article	IF	CITATIONS
73	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. The Lancet Global Health, 2015, 3, e358-e359.	2.9	39
74	Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine, 2015, 33, 4618-4622.	1.7	22
75	Altered Innate Immune Development in HIV-Exposed Uninfected Infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 245-255.	0.9	66
76	Emerging antiretroviral drug resistance in sub-Saharan Africa. Aids, 2014, 28, 2643-2648.	1.0	5
77	Hantaviruses in Africa. Virus Research, 2014, 187, 34-42.	1.1	42
78	Irreproducible positive results on the Cobas AmpliPrep/Cobas TaqMan HIV-1 Qual test are different qualitatively from confirmed positive results. Journal of Medical Virology, 2014, 86, 82-87.	2.5	19
79	Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome Coronavirus by Characterization of a Conspecific Virus from an African Bat. Journal of Virology, 2014, 88, 11297-11303.	1.5	337
80	A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. Journal of Clinical Virology, 2014, 60, 387-391.	1.6	9
81	Evidence of hantavirus infection in South Africa. International Journal of Infectious Diseases, 2014, 21, 182-183.	1.5	1
82	Evaluating a minipool strategy to screen for virologic failure and antiretroviral drug resistance. International Journal of Infectious Diseases, 2014, 21, 382.	1.5	0
83	The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine, 2013, 31, 5579-5584.	1.7	57
84	Pooled HIV-1 Viral Load Testing Using Dried Blood Spots to Reduce the Cost of Monitoring Antiretroviral Treatment in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 134-137.	0.9	23
85	Immune reconstitution hepatitis E. Aids, 2013, 27, 487-489.	1.0	20
86	Close Relative of Human Middle East Respiratory Syndrome Coronavirus in Bat, South Africa. Emerging Infectious Diseases, 2013, 19, 1697-1699.	2.0	317
87	Antibody Responses to Vaccination among South African HIV-Exposed and Unexposed Uninfected Infants during the First 2 Years of Life. Vaccine Journal, 2013, 20, 33-38.	3.2	70
88	Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. PLoS ONE, 2013, 8, e67188.	1.1	59
89	Construction of a High Titer Infectious HIV-1 Subtype C Proviral Clone from South Africa. Viruses, 2012, 4, 1830-1843.	1.5	2
90	High HBV Viral Loads in HIV-Infected Pregnant Women at a Tertiary Hospital, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e111-e112.	0.9	19

#	Article	IF	Citations
91	Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. Journal of Clinical Virology, 2012, 53, 106-109.	1.6	31
92	Emerging and re-emerging viral infections. , 2012, , 24-25.		0
93	Ontogeny of Toll-Like Receptor Mediated Cytokine Responses of South African Infants throughout the First Year of Life. PLoS ONE, 2012, 7, e44763.	1.1	35
94	Orthomyxoviruses., 2012,, 78-79.		0
95	The laboratory diagnosis of viral infections. , 2012, , 30-31.		0
96	HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-NaÃ-ve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. PLoS ONE, 2011, 6, e23091.	1.1	43
97	Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTIâ€based regimens in the western cape, South Africa. Journal of Medical Virology, 2011, 83, 1764-1769.	2.5	34
98	Cost-Effectiveness of Nucleic Acid Amplification Tests for Identifying Acute HIV Infections. Journal of Clinical Microbiology, 2011, 49, 1704-1704.	1.8	5
99	Optimising automation of a manual enzyme-linked immunosorbent assay. African Journal of Laboratory Medicine, 2011, 1, 15.	0.2	1
100	Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited Setting. Clinical Infectious Diseases, 2011, 52, 264-270.	2.9	52
101	HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts. Infectious Disorders - Drug Targets, 2011, 11, 167-174.	0.4	202
102	The Capacity of African Research Institutions to Respond to HIV/M. tuberculosis Co-Infection. The Open Infectious Diseases Journal, 2011, 5, 60-80.	0.6	0
103	Research Priorities for HIV/M. tuberculosis Co-Infection. The Open Infectious Diseases Journal, 2011, 5, 14-20.	0.6	0
104	Significantly Diminished Long-Term Specificity of the BED Capture Enzyme Immunoassay Among Patients With HIV-1 With Very Low CD4 Counts and Those on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 496-499.	0.9	64
105	NucliSens EasyQ® HIV-1 V1.2 system: Detection of human plasma-derived background signal. Journal of Virological Methods, 2010, 165, 318-319.	1.0	5
106	Young age a predictor of weak reactivity in a rapid antibody test in infants infected with HIV. Journal of Medical Virology, 2010, 82, 1314-1317.	2.5	4
107	Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clinical Chemistry and Laboratory Medicine, 2010, 48, 11-21.	1.4	15
108	SURVEILLANCE OF TRANSMITTED RESISTANCE TO ANTIRETROVIRAL DRUG CLASSES AMONG YOUNG CHILDREN IN THE WESTERN CAPE PROVINCE OF SOUTH AFRICA. Pediatric Infectious Disease Journal, 2010, 29, 370-371.	1.1	9

#	Article	IF	Citations
109	Prevalence- and Gender-Specific Immune Response to Opportunistic Infections in HIV-Infected Patients in Lesotho. Sexually Transmitted Diseases, 2010, 37, 454-459.	0.8	21
110	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. Pediatric Infectious Disease Journal, 2009, 28, 1125-1127.	1.1	44
111	Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. Journal of Medical Virology, 2008, 80, 942-946.	2.5	31
112	Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ® system. Journal of Virological Methods, 2008, 150, 80-81.	1.0	5
113	Phylogenetic Diversity and Low Level Antiretroviral Resistance Mutations in HIV Type 1 Treatment-Naive Patients from Cape Town, South Africa. AIDS Research and Human Retroviruses, 2008, 24, 1009-1012.	0.5	38
114	Reconstitution of Cytomegalovirus Specific T Cells after Pediatric Allogeneic Stem Cell Transplantation: Results from a Pilot Study Using a Multi-Allele CMV Tetramer Group. Klinische Padiatrie, 2008, 220, 348-352.	0.2	12
115	Molecular Analysis of HIV Type $1 < i > vif < i> $ Sequences from Cape Town, South Africa. AIDS Research and Human Retroviruses, 2008, 24, 991-994.	0.5	11
116	Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation. Journal of Clinical Virology, 2006, 35, 160-166.	1.6	8
117	Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. Journal of Clinical Virology, 2006, 37, 68-71.	1.6	31
118	Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 2006, 3, e237.	3.9	594
119	HIV-1 Viral Load Assays for Resource-Limited Settings: Clades Matter. PLoS Medicine, 2006, 3, e538.	3.9	13
120	Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus. Journal of Virology, 2006, 80, 6982-6992.	1.5	153
121	Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain. Clinical Chemistry, 2006, 52, 1258-1266.	1.5	92
122	Response to †Single phylogenetic reconstruction method is insufficient to clarify relationships between patient isolates in HIV-1 transmission case' by Jenwitheesuk and Liu. Aids, 2005, 19, 741-743.	1.0	3
123	Anti-HIV, Anti-Poxvirus, and Anti-SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet-V/anti-Vac Suggests That It Contains a Novel Broad-Spectrum Antiviral. Annals of the New York Academy of Sciences, 2005, 1056, 293-302.	1.8	36
124	Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Research, 2005, 66, 81-97.	1.9	62
125	Stability and inactivation of SARS coronavirus. Medical Microbiology and Immunology, 2005, 194, 1-6.	2.6	470
126	Bioterrorism: is it a real threat?. Medical Microbiology and Immunology, 2005, 194, 109-114.	2.6	8

#	Article	IF	CITATIONS
127	Kommerzielle Systeme zur Genotypisierung von humanen Immundefizienzviren Typ 1: Vergleich von ViroSeq (Abbott) und TruGene (Bayer). Commercially available assays for genotyping of human immunodeficiency virus type 1: Comparison of ViroSeq (Abbott) and TruGene (Bayer). Das Medizinische Laboratorium, 2005, 29, 50-62.	0.0	0
128	Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2005, 79, 1635-1644.	1.5	152
129	Virological laboratory diagnosis of SARS. , 2005, , 129-144.		0
130	Comparative evaluation of the Cobas Amplicor HIV-1 Monitorâ, Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitorâ, Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. Journal of Clinical Virology, 2005, 33, 43-51.	1.6	32
131	HBV reactivation after kidney transplantation. Journal of Clinical Virology, 2005, 32, 162-165.	1.6	61
132	HIV-1 genotyping: comparison of two commercially available assays. Expert Review of Molecular Diagnostics, 2004, 4, 281-291.	1.5	19
133	Activation of the Cytokine Network and Unfavorable Outcome in Patients with Yellow Fever. Journal of Infectious Diseases, 2004, 190, 1821-1827.	1.9	87
134	Das SARS-assoziierte Coronavirus – Die erste Pandemie des 21. Jahrhunderts / The SARS-associated coronavirus – The first pandemic of the 21st century. Laboratoriums Medizin, 2004, 28, 42-55.	0.1	0
135	Evaluation of Advanced Reverse Transcription-PCR Assays and an Alternative PCR Target Region for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus. Journal of Clinical Microbiology, 2004, 42, 2043-2047.	1.8	100
136	NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion, 2004, 44, 470-475.	0.8	24
137	Acute retinal necrosis six years after herpes simplex encephalitis: An elusive immune deficit suggested by insufficient test sensitivity. Journal of Medical Virology, 2004, 73, 250-255.	2.5	12
138	Severe acute respiratory syndrome (SARS)â€"paradigm of an emerging viral infection. Journal of Clinical Virology, 2004, 29, 13-22.	1.6	103
139	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, The, 2004, 363, 2139-2141.	6.3	252
140	Phylogenetic analysis of HIV-1 transmission. Aids, 2004, 18, 2109-2113.	1.0	27
141	Primary Cytomegalovirus Infection in an Outpatient Settingâ€"Laboratory Markers and Clinical Aspects. Infection, 2003, 31, 318-323.	2.3	47
142	Virology and epidemiology of oral herpesvirus infections. Medical Microbiology and Immunology, 2003, 192, 133-136.	2.6	2
143	Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma. Journal of Clinical Virology, 2003, 26, 49-59.	1.6	24
144	Severe acute respiratory syndrome: identification of the etiological agent. Trends in Molecular Medicine, 2003, 9, 325-327.	3.5	99

#	Article	IF	CITATIONS
145	Laboratory Diagnosis of Norovirus: Which Method Is the Best?. Intervirology, 2003, 46, 232-238.	1.2	67
146	Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976.	13.9	3,971
147	Viral Zoonoses – A Threat under Control?. Intervirology, 2003, 46, 71-78.	1.2	48
148	Role of China in the Quest To Define and Control Severe Acute Respiratory Syndrome. Emerging Infectious Diseases, 2003, 9, 1037-1041.	2.0	53
149	Variety of Interpretation Systems for Human Immunodeficiency Virus Type 1 Genotyping: Confirmatory Information or Additional Confusion?. Current Drug Targets Infectious Disorders, 2003, 3, 373-382.	2.1	26
150	Comparison of Nine Resistance Interpretation Systems for HIV-1 Genotyping. Antiviral Therapy, 2003, 8, 239-244.	0.6	55
151	Chemotherapeutika-Resistenz und neue Virusvarianten bei sexuell übertragbaren Infektionen/Chemotherapeutic Resistance and Novel Virus Variants in Sexually Transmitted Infections. Laboratoriums Medizin, 2002, 26, 474-485.	0.1	0
152	Quantifizierung von CMV-DNA als diagnostisches Werkzeug zur verbesserten Behandlung und berwachung von Risikopatienten/CMV Genome Quantification as a Diagnostic Tool for Improving Treatment and Monitoring of Risk Patients. Laboratoriums Medizin, 2002, 26, 486-494.	0.1	0
153	HHV-8 Seropräalenz in ausgewälten (Risiko)-Kollektiven im Raum Frankfurt am Main/HHV-8 Seroprevalence in Selected (Risk)-Groups in the Area of Frankfurt am Main. Laboratoriums Medizin, 2002, 26, 466-473.	0.1	0
154	Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. Journal of Antimicrobial Chemotherapy, 2002, 49, 713-721.	1.3	32
155	Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitorâ,, Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitorâ,, test (manual specimen preparation). Journal of Clinical Virology, 2002, 25, 103-107.	1.6	25
156	Performance characteristics of an automated PCR assay for the quantification of cytomegalovirus DNA in plasma. Journal of Virological Methods, 2002, 101, 149-157.	1.0	15
157	Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell-free cytomegalovirus. Journal of Medical Virology, 2002, 66, 518-523.	2.5	11
158	Polyomavirus Viruria in Bone Marrow Transplant Recipients: Lack of Correlation with Clinical Symptoms. Infection, 2002, 30, 91-93.	2.3	11
159	Travel-Acquired Dengue Infection: Clinical Spectrum and Diagnostic Aspects. Infection, 2002, 30, 225-228.	2.3	18
160	Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Medical Microbiology and Immunology, 2002, 190, 153-160.	2.6	43
161	Cross-reactivity in flavivirus serology: new implications of an old finding?. Medical Microbiology and Immunology, 2002, 190, 199-202.	2.6	82
162	Laboratory diagnosis of influenza - virology or serology?. Medical Microbiology and Immunology, 2002, 191, 157-160.	2.6	34

#	Article	IF	CITATIONS
163	Prevention of post-transfusion cytomegalovirus: leucoreduction or screening?. Vox Sanguinis, 2002, 83, 72-73.	0.7	7
164	The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. Journal of Clinical Virology, 2001, 20, 23-30.	1.6	47
165	Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. Journal of Clinical Virology, 2001, 20, 59-70.	1.6	68
166	Enterovirus Infections in Germany: Comparative Evaluation of Different Laboratory Diagnostic Methods. Infection, 2001, 29, 138-142.	2.3	14
167	Kaposi's sarcoma-associated herpesvirus seroprevalence in selected German patients: evaluation by different test systems. Medical Microbiology and Immunology, 2001, 190, 121-127.	2.6	22
168	False-negative HIV antibody test results. , 2000, 60, 43-47.		16
169	Cytomegalovirus Infection Decreases Expression of Thrombospondinâ€1 and â€2 in Cultured Human Retinal Glial Cells: Effects of Antiviral Agents. Journal of Infectious Diseases, 2000, 182, 643-651.	1.9	27
170	Quantitative molecular virology in patient management. Journal of Clinical Pathology, 2000, 53, 76-83.	1.0	16
171	No apparent effect of cidofovir in epidermodysplasia verruciformis. Journal of Clinical Virology, 2000, 16, 55-57.	1.6	19
172	Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. British Journal of Haematology, 2000, 111, 782-790.	1.2	17
173	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum American Journal of Tropical Medicine and Hygiene, 1999, 60, 142-145.	0.6	23
174	Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. Lancet, The, 1998, 352, 21-26.	6.3	647
175	Emerging viral pathogens in long-term expatriates (i): Hepatitis E Virus. Tropical Medicine and International Health, 1997, 2, 885-891.	1.0	10
176	Acute hepatitis E in catania (eastern sicily) 1980–1994. The role of hepatitis E virus. Infection, 1997, 25, 313-316.	2.3	57
177	Diphtheria immunity in health staff. Lancet, The, 1996, 347, 969.	6.3	9
178	Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus. Journal of Virological Methods, 1996, 57, 87-93.	1.0	33
179	Lack of correlation between different hepatitis C virus screening and confirmatory assays. Journal of Virological Methods, 1996, 59, 141-146.	1.0	9
180	Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Infection, 1996, 24, 384-389.	2.3	15

#	ARTICLE	IF	CITATIONS
181	Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 434-435.	0.7	46
182	Immunological Findings in HIV- <i>Leishmania</i> Coinfection. Intervirology, 1996, 39, 285-288.	1.2	31
183	Evaluation of the reliability of 6 current anti-HIV-1/HIV-2 enzyme immunoassays. Journal of Virological Methods, 1995, 55, 97-104.	1.0	20
184	W. Preiser (Frankfurt a. M.): Die rechtlichen Voraussetzungen fi¿½r bedingte vors�tzliche und fahrl�ssige Schuld. International Journal of Legal Medicine, 1959, 49, 583-586.	1.2	0
185	Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine. SSRN Electronic Journal, 0, , .	0.4	29
186	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	13.7	61